Groundbreaking CRISPR treatment for blindness only works for subset of patients
By Jocelyn Kaiser,
Science
| 11. 17. 2022
After some early but cautious optimism, a company is shelving its pioneering gene-editing treatment for a rare inherited blindness disorder. Editas Medicine announced today the trial trying to use the gene editor CRISPR to treat Leber congenital amaurosis 10 (LCA10) led to “clinically meaningful” vision improvements in only three of 14 patients.
In the study, patients received a subretinal injection of a modified virus carrying genetic material encoding components of CRISPR, a DNA-cleaving enzyme, and two RNA strands to guide the protein to its target sequences. For this trial, CRISPR was designed to snip out a problematic part of a gene called CEP290, which encodes a protein needed by the photoreceptor cells that eyes use to sense light. It was the first trial in the world to directly inject the gene-editing system into the body, rather than applying CRISPR to people’s cells in a lab dish and then reinfusing them.
Two of the patients whose vision improved—a woman treated early in the trial and a 14-year-old boy treated more recently, both of whom received midrange doses—had two defective copies...
Related Articles
Following a long-standing CGS tradition, we present a selection of our favorite Biopolitical Times posts of the past year.
In 2025, we published up to four posts every month, written by 12 authors (staff, consultants and allies), some in collaboration and one simply credited to CGS.
These titles are presented in chronological order, except for three In Memoriam notices, which follow. Many more posts that are worth your time can be found in the archive. Scroll down and “VIEW...
By Jonathan Matthews, GMWatch | 12.11.2025
In our first article in this series, we investigated the dark PR tactics that have accompanied Colossal Bioscience’s de-extinction disinformation campaign, in which transgenic cloned grey wolves have been showcased to the world as resurrected dire wolves – a...
By Jenny Lange, BioNews | 12.01.2025
A UK toddler with a rare genetic condition was the first person to receive a new gene therapy that appears to halt disease progression.
Oliver, now three years old, has Hunter syndrome, an inherited genetic disorder that leads to physical...
By Simar Bajaj, The New York Times | 11.27.2025
A common cold was enough to kill Cora Oakley.
Born in Morristown, N.J., with virtually no immune system, Cora was diagnosed with severe combined immunodeficiency, a rare genetic condition that leaves the body without key white blood cells.
It’s better...
